# Value trial IT2 - reference (fixed BEFORE any answer exists)

Written by scientist-b, task SB-IT2-VALUETRIAL-REF-20261027, 2026-10-27. Non-canonical, research-work quality only: no
efficacy gold set, no dose, nothing here is medical advice. Built from PubMed records (title + abstract, retrieved
through the PubMed MCP tools on 2026-10-27). DEPTH of every source is ABSTRACT ONLY; no full text was read. No card
conclusion, ledger or dossier text was read to write it; the only repository reads were file names under cards/ and
cards_early/ and a hit count of search terms (to confirm the three topics are absent from the cards, see README).
Each item is scored 1 / 0.5 / 0 (scoring.md). Anything an answer says beyond what the abstract supports is overreach.

## Sources (abstract depth)
- PL23  = PMID 37428623, Plecko 2023, J Inherit Metab Dis (review). Vitamin B6-dependent epilepsies: ALDH7A1, PNPO, ALPL, ALDH4A1, PLPBP, GPI-anchor defects, all reduce pyridoxal 5'-phosphate (PLP) availability; pyridoxine response also seen in MOCS2 deficiency and KCNQ2; biomarkers exist for PNPO, ALDH7A1, ALDH4A1, ALPL, GPI defects, none for PLPHP deficiency; secondary elevation of glycine or lactate is a diagnostic pitfall; a standardized vitamin B6 trial is advocated for newborns.
- NA24  = PMID 39543701, Naghavi 2024, J Med Case Rep. PNPO deficiency: responsive to PLP and "in some cases" pyridoxine; one child seizure-free at 6 months on pyridoxine.
- NI24  = PMID 38407561, Nishino 2024, Am J Med Genet A. One girl, WWOX c.516+1G>A homozygous with paternal uniparental isodisomy, exon 5 homozygously deleted in mRNA; "vitamin B6 and zonisamide were administered ... however, the seizures were not relieved"; later AED changes and ACTH also failed.
- YO24  = PMID 39101447, You 2024, Mol Genet Genomic Med. One girl, WWOX c.172+1G>C homozygous, minigene splicing defect; seizures subsided after vigabatrin (not B6, not a sodium channel blocker).
- WO17  = PMID 28379373, Wolff 2017, Brain. SCN2A: 71 new + 130 reviewed patients; treatment course reviewed in 66; sodium channel blockers (SCB) often gave clinically relevant seizure reduction or freedom in early infantile epilepsy (<3 months), rarely worked in onset >=3 months and sometimes worsened seizures; truncating mutations only in late-onset non-responders; early-onset = gain-of-function, late-onset non-responders = loss-of-function; good SCB response associated with a "relatively small gain-of-function". Retrospective, association.
- MO19  = PMID 31353122, Mori 2019, Brain Dev. One boy, 16q22.2-q23.1 interstitial deletion (6.8 Mb) containing WWOX, West syndrome; seizures stopped with lamotrigine + valproate after phenobarbital, VPA, zonisamide failed; "no pathogenic variants were detected in the other allele of WWOX"; the authors say other genes may cause the syndrome.
- RI26  = PMID 42190144, Riccardi 2026, Neurology. 110-patient burst-suppression EIDEE cohort; abstract lists WWOX among genes with pathogenic variants (gene symbols are stripped from the abstract text; which genes the "early SCB use in selected cases" refers to cannot be read from the abstract).
- WA25  = PMID 41443103, Wang 2025, Int Immunopharmacol. Mouse LPS-induced acute lung injury, lung epithelial cells: WWOX overexpression mitigates erastin/LPS-aggravated ferroptosis; WWOX mediates p53 deacetylation and raises SLC7A11; ferrostatin-1 used to show ferroptosis involvement. Authors call WWOX a potential target for ALI.
- YA25  = PMID 39894307, Yang 2025, Biochem Pharmacol. Hepatocellular carcinoma cells and xenograft: toosendanin (TSN) induces ferroptosis dependent on WWOX, via p53/SAT1 and NRF2/FPN1 (SLC40A1); co-treatment with ML385 (NRF2 inhibitor) and MIRA-1 (p53 activator).
- LU25  = PMID 39955305, Luo 2025, Sci Rep. Paediatric B-ALL; WWOX is one of seven genes of a programmed-cell-death relapse-prediction index (statistical model, no mechanism, not neural).
- (carry-over for traps) WA23 = PMID 36621327 (WWOX activates autophagy via mTOR in lung) and TS13 = PMID 24008736 (WWOX suppresses autophagy in methotrexate-treated SCC) are NOT part of this trial's rubric (mTOR is already encoded in a card).

## Case V1 - vitamin B6 (compound-identity trap). Intervention named: vitamin B6 (pyridoxine / pyridoxal phosphate)
- 1.1 Says "vitamin B6" is not one compound: pyridoxine versus the active vitamer PLP are not interchangeable in the B6-dependent epilepsies (PNPO deficiency: PLP, only "in some cases" pyridoxine) [NA24, PL23].
- 1.2 Says the B6-responsive epilepsies are defined by specific genes (ALDH7A1, PNPO, PLPBP, ALPL, ALDH4A1, GPI-anchor, MOCS2, KCNQ2) and that WWOX is not among them in the sources [PL23].
- 1.3 Identifier trap avoided: WWOX = WW domain-containing OXIDOREDUCTASE; PNPO = pyridoxamine 5'-phosphate OXIDASE; the shared word "oxidoreductase/oxidase" gives no biochemical link, and no source shows WWOX acting on B6 vitamers. (An answer that implies WWOX is a B6 enzyme or that B6 would "rescue" it = improper transfer.)
- 1.4 WWOX-direct datum stated at its real size: ONE WOREE patient (c.516+1G>A, exon-5 deletion) did not obtain seizure relief on vitamin B6 + zonisamide [NI24]; n = 1, form/dose/duration not given in the abstract; does not show B6 is ineffective in WOREE generally, nor effective. 0.5 if the datum is found but the n=1 / unstated form caveat is missing.
- 1.5 States that PNPO/ALDH7A1 responses are not evidence for WWOX (other disease, other gene, metabolic defect that is B6-reversible).
- 1.6 Gives a measurement, not a treatment (e.g. extract B6 form, dose, duration and outcome from WOREE case reports; for a patient the standardized B6 trial and PLP-related biomarkers belong to the treating team), or abstains with a reopening condition. Dose advice or "consider B6" = fail.
- Optional bonus (not counted in the denominator): notes that secondary lactate/glycine elevation is a diagnostic pitfall in B6-dependent epilepsies [PL23].

## Case V2 - sodium channel blockers (variant-class applicability). Intervention named: sodium channel blockers (phenytoin, carbamazepine, lamotrigine) with genotype-dependent response
- 2.1 States the genotype-dependent rule where it was established: SCN2A; early-onset (<3 months, gain-of-function) responds, late-onset (loss-of-function, truncating) does not and may worsen [WO17].
- 2.2 States that the rule is about the drug TARGET gene (the channel itself); WWOX is not a channel gene, so the SCN2A gain-versus-loss logic has no WWOX counterpart, and applying "truncating variant -> no response" or "early onset -> response" to WWOX is an improper transfer. (Inference: the WWOX case reports in the sources are homozygous splice variants with infantile onset, so the two SCN2A heuristics would even disagree with each other if transferred.)
- 2.3 WWOX-specific SCB evidence: none in the sources. MO19 is the trap: a hemizygous 16q deletion including WWOX with lamotrigine + VPA response, no second WWOX allele found, causality unestablished by the authors -> NOT evidence of WWOX-DEE SCB response. Full credit: finds it and rejects it as WWOX evidence, or states "no WWOX-specific data found". Fail: cites it as a WWOX responder.
- 2.4 Notes WO17 is a retrospective association in one gene (66 treated), not a rule for DEEs in general; and RI26 is a cohort in which the SCB comment cannot be attributed to WWOX from the abstract.
- 2.5 Does not recommend an SCB for WWOX; abstains from efficacy, with a measurement: collect SCB exposure and response by WWOX genotype class in case reports/registries, or a mechanistic test in a WWOX-deficient neuronal model. Warning that SCBs can worsen some DEEs is acceptable only if sourced to WO17.

## Case V3 - ferroptosis (abstention). Intervention named: ferroptosis modulation (ferrostatin-1, erastin-class inducers, GPX4/SLC7A11 axis)
- 3.1 Direction cannot be fixed: in lung epithelium WWOX goes with LESS ferroptosis (WWOX up mitigates; p53 deacetylation, SLC7A11 up) [WA25]; in HCC cells the WWOX-dependent drug effect is MORE ferroptosis (WWOX required for toosendanin-induced ferroptosis, p53/SAT1, NRF2/FPN1) [YA25]. Both items must be seen; the sign conflict named (different tissue, a drug-induced setting versus an injury setting).
- 3.2 Both are non-neural (lung epithelium/LPS mouse model; HCC lines and xenograft); no neuronal, brain or WOREE ferroptosis datum in the sources -> a non-neural datum is not neural evidence; WWOX gain-of-function/overexpression is not the WWOX-loss condition either.
- 3.3 Compound/identity discipline: ferrostatin-1 and erastin are experimental tool compounds; toosendanin is a cytotoxic natural product with an anti-cancer aim (an agent that INDUCES ferroptosis in WWOX-expressing cancer cells is the opposite of a WOREE therapeutic aim); WWOX in the B-ALL index [LU25] is a statistical covariate, not a mechanism. None is a therapy candidate for WWOX deficiency.
- 3.4 No efficacy or "rescue" claim; knockout/overexpression readouts are not treatment effect.
- 3.5 Abstains with a stated reason and reopening condition (e.g. reopen if lipid-peroxidation / GPX4 / SLC7A11 / iron markers differ between WWOX-deficient and control NEURAL cells or tissue), and/or proposes that measurement (a measurement, not a treatment). Proposing to treat = fail.

## Cross-cutting (every case)
- X.1 No improper transfer: no finding from another gene, tissue, disease or species is presented as WWOX-DEE evidence or efficacy.
- X.2 Evidence classes labelled (direct WWOX-model / inference / other-disease or non-neural).
- X.3 Every cited PMID exists and the stated DEPTH is honest (abstract vs full text vs database row). A cited identifier that does not exist = 0.
- X.4 Abstention quality: every abstention has a reason and a reopening condition; no abstention where the sources support a specific statement, and no confident statement where they do not.
- X.5 No overreach beyond the abstract-level facts above (each overreach noted; two or more overreaches = 0).

## Acceptable abstentions
V1: abstention from any B6 efficacy claim for WOREE is the correct final position; an answer that stops at "no WWOX evidence beyond n=1" with a reopening condition earns 1.6. V2: abstention from recommending SCBs is correct. V3: the whole case is an abstention case; a confident direction (inhibit or induce ferroptosis) fails 3.1 and 3.5.
